山东大学耳鼻喉眼学报 ›› 2024, Vol. 38 ›› Issue (2): 144-149.doi: 10.6040/j.issn.1673-3770.0.2022.042

• 综述 • 上一篇    下一篇

OCTA在病理性近视脉络膜新生血管应用及其在人工智能的研究进展

吴丽丽,曲毅   

  1. 山东大学齐鲁医院 老年医学科, 山东 济南 250012
  • 出版日期:2024-03-20 发布日期:2024-03-29
  • 通讯作者: 曲毅. E-mail:yiqucn@ sdu.edu.cn

Application of optical tomography angiography and artificial intelligence in choroidal neovascularization secondary to pathologic myopia

WU Lili, QU Yi   

  1. Department of Geriatrics, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Online:2024-03-20 Published:2024-03-29

PDF (PC)

463

摘要： 病理性近视(pathological myopia, PM)近年来发病率增高,是世界范围内导致视力障碍的主要原因,其不仅成为全球性的公共卫生问题,并且造成了沉重的社会负担。脉络膜新生血管(choroidal neovascularization, CNV)是PM的最严重并发症之一,它可以引起眼底黄斑区病变,导致视力下降,出现暗点,视物变形,视野缺损等,如长期不治疗可能导致失明。光学相干断层扫描血管成像(optical coherence tomography angiography, OCTA)技术是一种对视网膜、脉络膜自动精确分层,通过量化血流面积、无血流面积和血流密度区域,对视网膜、脉络膜多层面进行定性、定量的检查工具。OCTA在诊断PM继发的CNV中起到很大帮助,可以较为明确地显示新生血管的位置大小等。目前对于PM引起的CNV主要治疗方法有光动力治疗及抗血管内皮生长因子治疗,OCTA可以评估PM-CNV治疗效果,论文主要就近期关于OCTA在PM-CNV的诊断及治疗中应用的研究进行综述, 并讨论其与人工智能相结合进行脉络膜显像时存在的问题与发展前景,以期为临床开展相关工作提供参考。

关键词: 病理性近视, 脉络膜新生血管, 光学相干断层扫描血管成像, 人工智能

Abstract: In recent years, the incidence of pathological myopia (PM) has increased. PM is a global eyeblinding problem and a heavy social burden. Choroidal neovascularization (CNV) is a severe complication of PM that can cause macular disorders. This may lead to central scotoma, metamorphopsia, visual field loss, and eventually blindness if left treated. Optical coherence tomography angiography (OCTA) provides an automatic and accurate visualization of the layers of the retina and choroid, which allows a qualitative and quantitative description of the microvascular areas of the retina and choroid. OCTA can be used to detect the pathogenesis of high myopia, at the microvascular level of the retina. OCTA helps diagnose CNV secondary to PM due to its ability to show the position and size of the CNV. As management, photodynamic and antivascular endothelial growth factor therapies have been used. OCTA can be used to evaluate the therapeutic effect of PMCNV. This article provides an overview of the current research options on the diagnosis and treatment of CNV and discusses the problems and prospects when they are combined with artificial intelligence for choroidal imaging, to provide reference for clinical work.

Key words: Pathological myopia, Choroidal neovascularization, Optical coherence tomography angiography, Artificial intelligence

中图分类号: 

  • R774.1
[1] Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036-1042. doi:10.1016/j.ophtha.2016.01.006
[2] Fricke TR, Jong M, Naidoo KS, et al. Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling[J]. Br J Ophthalmol, 2018, 102(7): 855-862. doi:10.1136/bjophthalmol-2017-311266
[3] 刘益帆, 贾智艳, 刘平. 青少年近视危险因素综述[J]. 国际眼科杂志, 2016, 16(7): 1276-1278. doi:10.3980/j.issn.1672-5123.2016.7.17 LIU Yifan, JIA Zhiyan, LIU Ping. Review of juvenile myopia risk factors[J]. International Eye Science, 2016, 16(7): 1276-1278. doi:10.3980/j.issn.1672-5123.2016.7.17
[4] Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review[J]. Am J Ophthalmol, 2014, 157(1): 9-25.e12. doi:10.1016/j.ajo.2013.08.010
[5] Saw SM, Hong CY, Chia KS, et al. Nearwork and myopia in young children[J]. Lancet, 2001, 357(9253): 390. doi:10.1016/S0140-6736(05)71520-8
[6] Saw SM, Chua WH, Wu HM, et al. Myopia: gene-environment interaction[J]. Ann Acad Med Singap, 2000, 29(3): 290-297
[7] Fan Q, Barathi VA, Cheng CY, et al. Genetic variants on chromosome 1q41 influence ocular axial length and high myopia[J]. PLoS Genet, 2012, 8(6): e1002753. doi:10.1371/journal.pgen.1002753
[8] Pan CW, Dirani M, Cheng CY, et al. The age-specific prevalence of myopia in Asia: a meta-analysis[J]. Optom Vis Sci, 2015, 92(3): 258-266. doi:10.1097/OPX.0000000000000516
[9] Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy[J]. Am J Ophthalmol, 2015, 159(5): 877-883.e7. doi:10.1016/j.ajo.2015.01.022
[10] Ohno-Matsui K, Lai TY, Lai CC, et al. Updates of pathologic myopia[J]. Prog Retin Eye Res, 2016, 52: 156-187. doi:10.1016/j.preteyeres.2015.12.001
[11] Anand S, Fan VY, Zhang JH, et al. China's human resources for health: quantity, quality, and distribution[J]. Lancet, 2008, 372(9651): 1774-1781. doi:10.1016/S0140-6736(08)61363-X
[12] Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al. Myopic maculopathy: current status and proposal for a new classification and grading system(ATN)[J]. Prog Retin Eye Res, 2019, 69: 80-115. doi:10.1016/j.preteyeres.2018.10.005
[13] Cheung CMG, Ohno-Matsui K, Wong TY, et al. Influence of myopic macular degeneration severity on treatment outcomes with intravitreal aflibercept in the MYRROR study[J]. Acta Ophthalmol, 2019, 97(5): e729-e735. doi:10.1111/aos.14035
[14] Ohno-Matsui K, Ikuno Y, Lai TYY, et al. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia[J]. Prog Retin Eye Res, 2018, 63: 92-106. doi:10.1016/j.preteyeres.2017.10.005
[15] Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization[J]. Am J Ophthalmol, 2013, 155(5): 913-919. doi:10.1016/j.ajo.2012.11.021
[16] Ohno-Matsui K, Lai TY, Lai CC, et al. Updates of pathologic myopia[J]. Prog Retin Eye Res, 2016, 52: 156-187. doi:10.1016/j.preteyeres.2015.12.001
[17] 丁雯芝, 邹俊. 病理性近视脉络膜新生血管发病机制的研究进展[J]. 眼科新进展, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274 DING Wenzhi, ZOU Jun. Research advances in pathogenesis of choroidal neovascularization of pathologic myopia[J]. Recent Advances in Ophthalmology, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274
[18] Kojima A, Ohno-Matsui K, Teramukai S, et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2006, 244(11): 1474-1479. doi:10.1007/s00417-006-0324-4
[19] Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up[J]. Ophthalmology, 2003, 110(7): 1297-1305. doi:10.1016/S0161-6420(03)00461-5
[20] Miller DG, Singerman LJ. Natural history of choroidal neovascularization in high myopia[J]. Curr Opin Ophthalmol, 2001, 12(3): 222-224. doi:10.1097/00055735-200106000-00014
[21] Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey[J]. Ophthalmology, 1986, 93(5): 611-617. doi:10.1016/s0161-6420(86)33697-2
[22] Kwiterovich KA, Maguire MG, Murphy RP, et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study[J]. Ophthalmology, 1991, 98(7): 1139-1142. doi:10.1016/s0161-6420(91)32165-1
[23] Borrelli E, Sarraf D, Freund KB, et al. OCT angiography and evaluation of the choroid and choroidal vascular disorders[J]. Prog Retin Eye Res, 2018, 67: 30-55. doi:10.1016/j.preteyeres.2018.07.002
[24] Cohen SY, Miere A, Nghiem-Buffet S, et al. Clinical applications of optical coherence tomography angiography: what we have learnt in the first 3 years[J]. Eur J Ophthalmol, 2018, 28(5): 491-502. doi:10.1177/1120672117753704
[25] McCarthy J, Minsky M, Rochester N, et al. A proposal for the Dartmouth summer research project on artificial intelligence, August 31, 1955[J]. AI Mag, 2006, 27: 12-14. doi:10.1609/aimag.v27i4.1904
[26] Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation[J]. Chest, 2010, 137(2): 263-272. doi:10.1378/chest.09-1584
[27] Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs[J]. JAMA, 2016, 316(22): 2402-2410. doi:10.1001/jama.2016.17216
[28] Yim J, Chopra R, Spitz T, et al. Predicting conversion to wet age-related macular degeneration using deep learning[J]. Nat Med, 2020, 26(6): 892-899. doi:10.1038/s41591-020-0867-7
[29] Li ZX, He YF, Keel S, et al. Efficacy of a deep learning system for detecting glaucomatous optic neuropathy based on color fundus photographs[J]. Ophthalmology, 2018, 125(8): 1199-1206. doi:10.1016/j.ophtha.2018.01.023
[30] Garcia GP, Lavieri MS, Andrews C, et al. Accuracy of Kalman filtering in forecasting visual field and intraocular pressure trajectory in patients with ocular hypertension[J]. JAMA Ophthalmol, 2019, 137(12): 1416-1423. doi:10.1001/jamaophthalmol.2019.4190
[31] Sayanagi K, Hara C, Fukushima Y, et al. Flow pattern and perforating vessels in three different phases of myopic choroidal neovascularization seen by swept-source optical coherence tomography angiography[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2021, 259(9): 2615-2624. doi:10.1007/s00417-021-05134-y
[32] Li SS, Sun LM, Zhao XJ, et al. Assessing the activity of myopic choroidal neovascularization: comparison between optical coherence tomography angiography and dye angiography[J]. Retina, 2020, 40(9): 1757-1764. doi:10.1097/IAE.0000000000002650
[33] Bruyère E, Miere A, Cohen SY, et al. Neovascularization secondary to high myopia imaged by optical coherence tomography angiography[J]. Retina, 2017, 37(11): 2095-2101. doi:10.1097/IAE.0000000000001456
[34] Lai TYY, Cheung CMG. Myopic choroidal neovascularization: diagnosis and treatment[J]. Retina, 2016, 36(9): 1614-1621. doi:10.1097/IAE.0000000000001227
[35] Muakkassa NW, Chin AT, de Carlo T, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography[J]. Retina, 2015, 35(11): 2252-2259. doi:10.1097/IAE.0000000000000836
[36] Querques L, Giuffrè C, Corvi F, et al. Optical coherence tomography angiography of myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2017, 101(5): 609-615. doi:10.1136/bjophthalmol-2016-309162
[37] Mao JB, Shao YR, Yu JF, et al. Macular density alterations in myopic choroidal neovascularization and the effect of anti-VEGF on it[J]. Int J Ophthalmol, 2021, 14(8): 1205-1212. doi:10.18240/ijo.2021.08.11
[38] Uematsu S, Sakaguchi H, Sayanagi K, et al. Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization[J]. Sci Rep, 2021, 11(1): 21947. doi:10.1038/s41598-021-01557-z
[39] Cohen SY, Tabary S, El Ameen A, et al. Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2019, 257(3): 485-493. doi:10.1007/s00417-018-04205-x
[40] Cheng LN, Lin YX, Liu L, et al. Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography[J]. Sci Rep, 2020, 10(1): 16959. doi:10.1038/s41598-020-74073-1
[41] Cennamo G, Montorio D, Mazzella G, et al. Retinal and choriocapillaris vascular changes in patients affected by different clinical phenotypes of β-thalassemia: an optical coherence tomography angiography study[J]. Biology, 2021, 10(4): 276. doi:10.3390/biology10040276
[42] Giorno P, Iacono P, Scarinci F, et al. Microvasculature changes of myopic choroidal neovascularization and the predictive value of feeder vessel disappearance after ranibizumab treatment revealed using optical coherence tomography angiography[J]. Ophthalmologica, 2020, 243(4): 263-270. doi:10.1159/000504755
[43] Ueda-Consolvo T, Shibuya N, Oiwake T, et al. Using optical coherence tomography angiography to guide myopic choroidal neovascularization treatment: a 3-year follow-up study[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2021, 259(11): 3295-3303. doi:10.1007/s00417-021-05270-5
[44] Wang J, Hormel TT, Gao LQ, et al. Automated diagnosis and segmentation of choroidal neovascularization in OCT angiography using deep learning[J]. Biomed Opt Express, 2020, 11(2): 927-944. doi:10.1364/BOE.379977
[45] Sawai, Miyata M, Uji A, et al. Usefulness of denoising process to depict myopic choroidal neovascularisation using a single optical coherence tomography angiography image[J]. Sci Rep, 2020, 10(1): 6172. doi:10.1038/s41598-020-62607-6
[1] 杨冠英,李元彬. 人工智能在干眼管理中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 115-120.
[2] 赵娟,焦万珍,赵博军. UWFSS-OCTA检测糖尿病视网膜病变微循环的变化[J]. 山东大学耳鼻喉眼学报, 2026, 40(2): 80-86.
[3] 朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[4] 程卓, 梁辉, 邢鲁民. 深度学习技术在咽喉内镜应用中的研究进展及前景分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 112-119.
[5] 李世强,马燕,王家伟. 光学相干断层扫描血管成像在全身疾病中的临床应用研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 127-134.
[6] 张国明,魏文斌,林浩添,迟玮,张少冲,赵培泉,雷柏英,陈有信,王雨生,何明光,梁建宏,卢海,陆方,黄欣,梁小玲,赵欣予,吴桢泉,余震,崔凯璇,刘亚玲,项道满,陈长征,张自峰,林铎儒,于珊珊,孙悦,檀韬,陈燕先,彭婕,董力,程湧,朱雪梅,杨鹏,陈少滨. 人工智能技术辅助早产儿视网膜病变诊疗专家共识(2025)[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 1-5.
[7] 沈嘉琪,李潇飒,毕燕龙,张敬法. 人工智能在DME筛查、诊断和预后中的应用[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 153-159.
[8] 谢玉林,雷大鹏. 人工智能在头颈部鳞状细胞癌淋巴结转移的病理研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 124-129.
[9] 王新钰,高丽芬,路晖,宋文琦,杨钰. 帕金森疾病的相关视网膜表现[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 156-162.
[10] 张一彤,李青香,石争浩,尚磊,袁钰淇,曹子讷,麻莉娜,刘海琴,任晓勇,施叶雯. 阻塞性睡眠呼吸暂停儿童睡眠结构研究及睡眠结构判读模型建立[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 126-132.
[11] 张晓晗,魏丽,杨凯莉,陈海燕,李彦松,王平. 中医辨证论治前后CSC患者OCTA变化及其与视力的相关性研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 115-122.
[12] 杜曰山一,王鲜,张国明. 人工智能辅助早产儿视网膜病变诊疗新进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 157-162.
[13] 初宝睿,曲毅. 载siIKKβ脂质纳米粒的制备及其对巨噬细胞再极化的作用[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 91-97.
[14] 刘佳钰,樊慧明,邹游,陈始明. 人工智能在鼻咽癌诊断与治疗中的应用研究进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 135-142.
[15] 李鹏伟,苏光明,刘江川,穆雅林. 光学相干断层扫描血管成像在2型黄斑毛细血管扩张症中的应用进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 140-144.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发